{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:13Z","timestamp":1793159833290,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eprac.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:28:35Z","timestamp":1778891315000},"page":"1488-1496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8685-3925","authenticated-orcid":false,"given":"Cheng-Hsien","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Shun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James","family":"Cheng-Chung Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eprac.2026.05.010_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.05.010_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.05.010_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.eprac.2026.05.010_bib4","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2337\/dc21-1993","article-title":"GLP-1RAs for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease","volume":"45","author":"Hung","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.05.010_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2017.10.003","article-title":"Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: a large retrospective UK cohort study","volume":"196","author":"Anyanwagu","year":"2018","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.010_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like Peptide-1 receptor agonist vs Dipeptidyl Peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.010_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2026.05.010_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154799","article-title":"Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"120","author":"Prattichizzo","year":"2021","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.eprac.2026.05.010_bib9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.010_bib10","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.010_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eprac.2026.05.010_bib13","article-title":"Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial","volume":"55","author":"Gamborg","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like Peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eprac.2026.05.010_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.05.010_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103213","article-title":"Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study","volume":"83","author":"Wolff Sagy","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.010_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2026.05.010_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like Peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eprac.2026.05.010_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107481","article-title":"Methodological considerations in assessing GLP-1 receptor agonists and gastrointestinal cancer risk","volume":"210","author":"Hung","year":"2024","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.010_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.58205","article-title":"GLP-1 receptor agonists plus progestins and endometrial cancer risk in nonmalignant uterine diseases","volume":"9","author":"Yen","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.eprac.2026.05.010_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21878","article-title":"Cancer risk concerns and communication gaps regarding GLP-1 medications","volume":"8","author":"Attar-Olyaee","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00011-025-02170-w","article-title":"Comparison of cancer risks associated with JAK inhibitors and TNF inhibitors treatment in patients with rheumatoid arthritis: a systematic review and meta-analysis of real-world cohort studies","volume":"75","author":"Yang","year":"2026","journal-title":"Inflamm Res"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.010_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.010_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eprac.2026.05.010_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/dom.70131","article-title":"Impact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: a target trial emulation study","author":"Lee","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.05.010_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70450","article-title":"Editorial: the essential role of emulated clinical trial designs in TriNetX studies: avoiding confounding by indication","volume":"28","author":"Chen","year":"2025","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.eprac.2026.05.010_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70204","article-title":"Comparative effectiveness of TNF-\u03b1 and IL-6 inhibitors on bone health outcomes and mortality in rheumatoid arthritis patients: a retrospective cohort study","volume":"28","author":"Wang","year":"2025","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.010_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.05.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112109","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: a multi-institutional TriNetX study","volume":"222","author":"Hung","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.010_bib30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.010_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9556","article-title":"Association of overweight, obesity, and recent weight loss with colorectal cancer risk","volume":"6","author":"Mandic","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.010_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eprac.2026.05.010_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.eprac.2026.05.010_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31083\/j.fbl2810259","article-title":"The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage","volume":"28","author":"Pu","year":"2023","journal-title":"Front Biosci (Landmark Ed"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.010_bib35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/dme.14287","article-title":"Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes","volume":"37","author":"Rouette","year":"2020","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-023-11077-w","article-title":"High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.eprac.2026.05.010_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2017.05.015","article-title":"Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells","volume":"809","author":"Krause","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.010_bib39","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.010_bib40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like Peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.010_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA use and thyroid cancer risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"8","key":"10.1016\/j.eprac.2026.05.010_bib43","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1097\/JS9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.eprac.2026.05.010_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijsu.2018.07.013","article-title":"The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis","volume":"57","author":"Yin","year":"2018","journal-title":"Int J Surg"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.010_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15248","article-title":"Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: population-based cohort study","volume":"41","author":"Pradhan","year":"2024","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.010_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2024.2400797","article-title":"Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis","volume":"10","author":"Obaid","year":"2024","journal-title":"Future Sci OA"},{"issue":"6","key":"10.1016\/j.eprac.2026.05.010_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003550","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study","volume":"11","author":"Pradhan","year":"2023","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:44:56Z","timestamp":1790761496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1530891X26009870"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.05.010","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}